Which type of pertussis vaccine (acelullar pertussis vaccine (aP) or wholecell pertussis vaccine (wP)) should be recommended for use in national immunization programmes? Policy recommendations are derived from the results of the following comparisons of the profiles of the vaccines in terms of:

  • The quality of the evidence on benefits and harms
  • The effect of wP vs aP vaccine on clinically important outcomes and harms
  • The resource implications related to the cost of aP and wP vaccine
  • The values and preferences as well as equity implications
  • Evidence to recommendation table
  • Pertussis